Levemir insulin, a long-acting insulin analog for diabetes management, has not been discontinued globally. However, its availability has been affected by manufacturing and supply chain issues, leading to shortages and temporary discontinuations in certain regions.
Why Are There Shortages of Levemir?
Reports indicate that the availability of Levemir has been impacted by manufacturing capacity limitations. This has led to a reduced supply in various markets. [1]
What Are the Alternatives to Levemir?
For individuals who rely on Levemir, alternative long-acting insulin options are available. These include other insulin analogs such as Lantus (insulin glargine) and Tresiba (insulin degludec), as well as older forms of insulin. Patients should consult with their healthcare provider to determine the most suitable alternative based on their individual needs and treatment plan. [2]
When Does Levemir's Patent Expire?
The patent protection for Levemir (insulin detemir) has largely expired or is nearing expiration in many key markets. For instance, its U.S. patent expired in late 2019. [3] The expiration of patents opens the door for the potential development and market entry of generic or biosimilar versions. DrugPatentWatch.com provides detailed information on drug patent statuses. [4]
Can Generic or Biosimilar Versions of Levemir Be Used?
With patent expirations, the pathway for generic or biosimilar insulins to enter the market is established. Biosimilar insulins are highly similar to the reference biologic product in terms of safety, purity, and potency. The availability and uptake of these alternatives can depend on regulatory approvals and market dynamics. [5]